Target intelligence / Profile preview

Proline rich 5, renal–Rho GTPase activating protein 8 readthrough (PRR5-ARHGAP8)

Target
PRR5-ARHGAP8
Molecular classification
Other (fusion/chimeric protein; readthrough transcript between adjacent genes), Contains domains characteristic of the RhoGAP family[4]
01

Overview

Proline rich 5, renal–Rho GTPase activating protein 8 readthrough (PRR5-ARHGAP8) is a naturally occurring human fusion transcript formed by transcriptional read-through between the neighboring PRR5 and ARHGAP8 genes[4][1]. The resulting fusion protein contains sequence elements from both parental gene products, including domains typical of RhoGAP proteins. The biological function of PRR5-ARHGAP8 itself has not been determined experimentally; however, PRR5 is a subunit of the mTORC2 kinase complex involved in neuronal survival, energy regulation, and proliferation, while ARHGAP8 is a GAP family protein regulating cytoskeletal dynamics and Rho GTPase signaling[1][2][4]. Expression of this fusion protein occurs at low levels and appears tissue-specific. Genome-wide association studies suggest a possible link to binge eating behavior in the context of bipolar disorder, but no direct therapeutic, biomarker, or disease-modifying roles have been confirmed for the fusion at present[1][4].

Other names
PRR5-ARHGAP8 fusion proteinPRR5-ARHGAP8 fusionPRR5-ARHGAP8B1AHC3 Protein
02

Mechanism of action

None established for direct targeted inhibition or activation—mechanism unknown.

03

Biological functions

Unknown specific functionRelated parent genes: mTORC2 regulation (PRR5) and Rho GTPase inactivation (ARHGAP8)[1][4]May contribute to cytoskeletal regulation, neuronal survival, proliferation, energy balance, and cell motility in line with parent gene functions[1][2]
04

Disease associations

Possible genetic association with binge eating behavior, especially in bipolar disorder patients[1]Candidate molecular roles in neurological disease and cell signaling disorders (extrapolated from parent gene functions)[1][4]Associated diseases from gene resources: Mitochondrial Complex I Deficiency, Nuclear Type 33, Kanzaki Disease (uncertain specific relevance)[4]
05

Safety considerations

None reported.Therapeutic targeting challenges are not defined due to lack of mechanistic and disease role data.
06

Interacting drugs

None known. No drugs are established to target PRR5-ARHGAP8 directly[4]
07

Biomarkers

None established. No clinical use as a biomarker for patient selection or monitoring[4][1]

Beyond the preview

Go deeper on Proline rich 5, renal–Rho GTPase activating protein 8 readthrough (PRR5-ARHGAP8).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Proline rich 5, renal–Rho GTPase activating protein 8 readthrough (PRR5-ARHGAP8).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call